Using a rat model of moderate obesity and insulin resistance and a cell model of hepatocyte steatosis, we report up-regulation of adiponectin, Sirt1/6, and downstream targets of Sirt1/6, and also, increases in both LKB1 and AMPK activities following RGZ treatment. The gene discussed is ADIPOQ; the disease is Insulin resistance.